For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$477.36
Thesis
Vertex runs a near-monopoly in cystic fibrosis with the Trikafta/Kaftrio franchise generating roughly $10B+ in annual revenue, funding one of biotech's most disciplined R&D engines. That cash flow is now backing a diversification beyond CF into gene editing and non-opioid pain, which transforms the story from a single-disease specialist into a multi-franchise platform.
Casgevy, partnered with CRISPR Therapeutics, is the first FDA-approved CRISPR/Cas9 therapy and addresses sickle cell disease and transfusion-dependent beta thalassemia. Journavx (suzetrigine), approved January 2025, is a first-in-class NaV1.8 inhibitor for moderate-to-severe acute pain, opening a non-opioid category the company can own commercially.
Catalysts
- Casgevy patient activations and authorized treatment center ramp
- Journavx adoption in post-surgical settings and label expansion into chronic pain
- Next-gen CF triple combo (vanzacaftor) cannibalization economics
- Pipeline readouts in APOL1-mediated kidney disease and type 1 diabetes cell therapy
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jul 21Trial initiationClinicalTrials.gov
Phase 2 trial (NCT07501702) of povetacicept in generalized myasthenia gravis recruiting, sponsored by Vertex.
- Jul 21OtherClinicalTrials.gov
Vertex Phase 3 trial NCT05444257 (VX-121 combo) status updated to ACTIVE_NOT_RECRUITING
- Jul 21Trial readoutClinicalTrials.gov
Phase 3 trial NCT05331183 (ELX/TEZ/IVA long-term safety/efficacy, non-F508del) status updated to ACTIVE_NOT_RECRUITING.
- Jul 20Trial initiationClinicalTrials.gov
Vertex initiates Phase 2/3 trial (NCT07204275) of povetacicept in primary membranous nephropathy; status recruiting.
- Jul 20Trial initiationClinicalTrials.gov
Phase 3 trial NCT07231419 recruiting for suzetrigine in diabetic peripheral neuropathy pain (Vertex sponsor).
- Jul 7OtherSEC
8-K filing (items 1.01, 7.01, 8.01, 9.01) on entry into material definitive agreement and related disclosures.
- Jul 1Trial initiationClinicalTrials.gov
Vertex updates NCT05356195 phase 3 trial of CTX001 in pediatric TDT; status ACTIVE_NOT_RECRUITING as of 2026-07-01.
- Jul 1OtherClinicalTrials.gov
Phase 3 trial NCT05329649 (CTX001 pediatric SCD) status updated to ACTIVE_NOT_RECRUITING